A Multicenter Phase 1/2B Study Of The Bruton?S Tyrosine Kinase Inhibitor, Ibrutinib (Pci-32765), In Combination With Carfilzomib (Kyprolis?) In Subjec
Posted Date: May 15, 2019
- Investigator: Tahir Latif
- Type of Study: Drug
The study drug Ibrutinib (PCI-32765 or IMBRUVICA?) is a type of drug called a kinase inhibitor. Kinases are proteins that help cells live and grow. The specific kinase blocked by ibrutinib is believed to help blood cancer cells live and grow. By inhibiting the activity of this specific kinase, it
Criteria:
To Be Eligible For This Study, Patients Must Have Multiple Myeloma
Keywords:
Pcyc-1119-Ca, Phase I, Cancer, Multiple Myeloma, Hematology
For More Information:
Uc Cancer Center
513-584-7698
kastla@uc.edu